Gabapentin Capsule
Product Images NDC 50090-7388

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-7388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A mathematical formula illustrating the calculation of creatinine clearance (CLCr) based on patient age, weight, serum creatinine levels, and a factor for female patients. This image likely appears in the pharmacokinetic or dosing information section of a drug label.*

FDA Label Image

Fig 1 (Fig 1)

A line graph titled 'Weekly Mean Pain Scores' from a clinical study comparing placebo and gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. Two curves represent mean pain scores for placebo and gabapentin over the study period, showing a trend of decreasing pain scores with gabapentin compared to placebo.*

FDA Label Image

Fig 2 (Fig 2)

Line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' presenting mean pain scores over a 7-week period. The graph compares three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day, showing the pain score trends during a 3-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Fig 3 (Fig 3)

A bar graph showing the proportion of responders with at least 50% reduction in pain score at endpoint in controlled PHN studies. Two studies (Study 1 and Study 2) are compared, with placebo (PBO) and gabapentin (GBP) doses indicated. Study 1 shows 12% response for placebo and 29% for GBP 3600. Study 2 shows responses of 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is noted with p-values <0.01 and <0.001.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot chart titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study' depicting data from three studies (Study a, Study b, Study c) in patients aged 12 years and older with partial seizures. The x-axis represents daily dose in milligrams (600 to 1800 mg), and the y-axis shows the difference in responder rate percentage (2% to 22%). Distinct markers differentiate the three studies across various dosages.*

FDA Label Image

Structure (Struct)

Chemical structure diagram of gabapentin showing its cyclohexane ring attached to amino and carboxyl functional groups.*

FDA Label Image

Label Image (Lbl500907388)

Label for GABAPENTIN 100 mg capsules, a human prescription drug for oral use. The label states that each capsule contains 100 mg of gabapentin USP. It includes storage instructions to store at 77 degrees Fahrenheit. The package contains 30 capsules and is labeled by A-S Medication Solutions in Libertyville, Illinois. The NDC number 50090-7388-0 is visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.